Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineFernando P. Polack, William C. Gruber, Ruth Bailey et al.|New England Journal of Medicine|2020Cited by 15.7k
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in AdolescentsRobert W. Frenck, William C. Gruber, Nicola P. Klein et al.|New England Journal of Medicine|2021Cited by 937
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 VaccineStephen J. Thomas, Kathrin U. Jansen, Edson Duarte Moreira et al.|medRxiv|2021Cited by 144
Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-oldRobert W. Frenck, William C. Gruber, Nicola P. Klein et al.|Future Virology|2023Cited by 3
Plain Language Summary of Pfizer-BioNTech BNT162b2 COVID-19 Vaccine Safety in Participants at Least 16 Years Old and Protection Against COVID-19 in Participants at Least 12 Years OldStephen J. Thomas, Kathrin U. Jansen, Edson Duarte Moreira et al.|Future Virology|2022Cited by 0